Creating therapeutic Disulfide-Rich Peptides targeting transmembrane proteins including
ion channels,GPCRs, and transporters

Creating therapeutic Disulfide-Rich Peptides targeting transmembrane proteins including ion channels,GPCRs, and transporters

What is the DRP?

Rigid peptides with three or more disulfide bonds in the molecule
Excellent modality to target membrane proteins for drug discovery
High resistance to digestive enzymes

High thermal stability

Rigid peptides with three or more disulfide bonds in the molecule
Excellent modality to target membrane proteins for drug discovery
High resistance to digestive enzymesHigh thermal stability

PERISS (Periplasm Secretion and Selection)
Innovative peptide screening technology to target membrane proteins

  • Evolutionary molecular engineering of peptides utilizing E. coli
  • Input a large DRP library with a diversity of up to 1 billion
  • Expression and targeting of full-length membrane proteins
    such as ion channels and GPCRs in the inner membrane of E. coli

Click to go to Veneno‘s YouTube page  

PERISS (Periplasm Secretion and Selection)
Innovative peptide screening technology to target membrane proteins

Evolutionary molecular engineering of peptides utilizing E. coli
Input a large DRP library with a diversity of up to 1 billion
Expression and targeting of full-length membrane proteins such as ion channels and GPCRs in the inner membrane of E. coli

PERISS (Periplasm Secretion and Selection)
Innovative peptide screening technology to target membrane proteins

PERISS(Periplasm Secretion and Selection)
Innovative peptide screening technology to target membrane proteins

Evolutionary molecular engineering of peptides utilizing E. coli
Input a large DRP library with a diversity of up to 1 billion
Expression and targeting of full-length membrane proteins such as ion channels and GPCRs in the inner membrane of E. coli

Company

Company name

Veneno Technologies Co. Ltd.

Establishment

July 2020

Head office

2-1-6 Sengen, Tsukuba, Ibaraki, 305-0047, Japan

Contact

info@veneno.jp

Representative

Kazunori Yoshikawa

Business

Research and development of novel drug, agrichemicals, and biochemicals

Management

Kazunori Yoshikawa

Representative Director, President, CEO

Tadashi Kimura, Ph.D.

Director, CSO and CTO

Shoichi Ozawa

External Director

Keisuke Nakano, CPA

Auditor

Our Business Models

We focus on two business models with a mission to develop peptide drugs and agrochemical ingredients based on DRP.

Drug Discovery Partnering

  We develop tailor-made functional DRPs in collaboration with our clients using our screening platform technology.

License-out of In-house pipeline

  We license out the developed drug candidate DRPs to pharmaceutical companies.

CONTACT

Veneno Technologies Co. Ltd.

2-1-6 Sengen Tsukuba, Ibaraki, 305-0047, Japan

info@veneno.jp